Advertisement

Opioids pp 189-216 | Cite as

Opioid Receptor-Coupled Second Messenger Systems

  • S. R. Childers
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 104 / 1)

Abstract

Most neurotransmitter and hormone receptors can be grouped into a series of receptor “superfamilies.” Receptors in each of these groups share a number of common properties, including general protein subunit structure, primary sequence homologies, and general gene structure and regulation. Receptors within each of these groups also share common effector systems and, in many cases, the effector systems themselves actually define the individual receptor superfamilies. Most neurotransmitters belong to two major receptor groups: the oligomeric receptor-ion channel complexes, and the G-protein-linked receptors. For neurotransmitters like GABA (acting at GABAA receptors) and acetylcholine (acting at nicotinic sites), receptors are large multisubunit structures which complex together to form ion channels integrated with the receptor-binding sites. For dopamine, norepinephrine, acetylcholine (acting at muscarinic receptors), and many neuropeptides, receptors are coupled to specific G proteins which activate a series of effector systems, several of which are associated with diffusible second messenger systems.

Keywords

Adenylate Cyclase Opioid Receptor Adenylyl Cyclase Guanine Nucleotide Opiate Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amatruda TT, Gautam N, Fong HKW, Northup JK, Simon MI (1988) The 35- and 36-kDa β subunits of GTP-binding regulatory proteins are products of separate genes. J Biol Chem 263: 5008–5011PubMedGoogle Scholar
  2. Attali B, Saya D, Vogel Z (1989a) Kappa-opiate agonists inhibit adenylate cyclase and produce heterologous desensitization in rat spinal cord. J Neurochem 52: 360–369PubMedGoogle Scholar
  3. Attali B, Saya D, Nah SY, Vogel Z (1989b) Kappa opiate agonists inhibit Ca2+ influx in rat spinal cord-dorsal root ganglion cocultures. Involvement of a GTP- binding protein. J Biol Chem 264: 347–353PubMedGoogle Scholar
  4. Beart PM, O’Shea RD, Manallack DT (1989) Regulation of sigma-receptors: high- and low-affinity agonist states, GTP shifts and up-regulation by rimcazole and 1, 3-di(2-tolyl)guanidine. J Neurochem 53: 779–788PubMedGoogle Scholar
  5. Beitner DB, Duman RS, Nestler EJ (1989) A novel action of morphine in the rat locus coeruleus: persistent decrease in adenylate cyclase. Mol Pharmacol 35: 559–564PubMedGoogle Scholar
  6. Birnbaumer L, Abramowitz J, Brown AM (1990) Receptor-effector coupling by G-proteins. Biochim Biophys Acta 1031: 163–224PubMedGoogle Scholar
  7. Blume AJ (1978a) Interactions of ligands with opiate receptors of brain membranes: regulation by ions and nucleotides. Proc Natl Acad Sci USA 75: 1713–1717PubMedGoogle Scholar
  8. Blume AJ (1978b) Opiate binding to membrane preparations of neuroblastoma- glioma hybrid cells NG108-15: effects of ions and nucleotides. Life Sci 22: 1843–1852PubMedGoogle Scholar
  9. Blume AJ, Lichtshtein L, Boone G (1979) Coupling of opiate receptors to adenylate cyclase: requirement for sodium and GTP. Proc Natl Acad Sci USA 76: 5626–5630PubMedGoogle Scholar
  10. Bourne H (1988) Cold Spring Harbor Symp Quant Biol 53: 203–208Google Scholar
  11. Breiweiser GE, Szabo G (1985) Uncoupling of cardiac muscarinic and β-adrenergic receptors from ion channels by a guanine nucleotide analogue. Nature 316: 538–540Google Scholar
  12. Bunn SJ, Marley PD, Livett BG (1988) Effects of opioid compounds on basal and muscarinic induced accumulation of inositol phosphates in cultured bovine chromaffin cells. Biochem Pharmacol 37: 395–399PubMedGoogle Scholar
  13. Cassel D, Selinger Z (1976) Catecholamine-stimulated GTPase activity in turkey erythrocyte membranes. Biochim Biophys Acta 452: 538–551PubMedGoogle Scholar
  14. Cerione RA, Codina J, Benovic JL, Lefkowitz RJ, Birnbaumer L, Caron MG (1984) The mammalian beta-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory guanine nucleotide binding protein of the adenylate cyclase system. Biochemistry 23: 4519–4525PubMedGoogle Scholar
  15. Cerione RA, Regan JW, Nakata H, Codina J, Benovic JL, Geirschik P, Somers RL, Spiegel AM, Birnbaumer L, Lefkowitz RJ, Caron MG (1986a) Functional reconstitution of alpha(2)-adrenergic receptors with guanine nucleotide regulatory proteins in phospholipid vesicles. J Biol Chem 261: 3901–3909PubMedGoogle Scholar
  16. Cerione RA, Staniszewski C, Gierschik P, Codina J, Somers R, Birnbaumer L, Spiegel AM, Caron MG, Lefkowitz RJ (1986b) Mechanism of guanine nucleotide regulatory protein-mediated inhibition of adenylate cyclase: studies with isolated subunits of transducin in a reconstituted system. J Biol Chem 261: 9514–9520PubMedGoogle Scholar
  17. Cerione RA, Gierschik P, Staniszewski C, Benovic JL, Codina J, Somers R, Birnbaumer L, Spiegel AM, Lefkowitz RJ, Caron MG (1987) Functional differences in the βγ complexes of transducin and the inhibitory guanine nucleotide regulatory protein. Biochemistry 26: 1485–1491PubMedGoogle Scholar
  18. Chang KJ, Hazum E, Killian A, Cuatrecasas P (1981) Interactions of ligands with morphine and enkephalin receptors are differentially affected by guanine nucleotides. Mol Pharmacol 20: 1–7PubMedGoogle Scholar
  19. Chen GG, Chalazonitis A, Shen KF, Crain SM (1988) Inhibitor of cyclic AMP- dependent protein kinase blocks opioid-induced prolongation of the action potential of mouse sensory ganglion neurons in dissociated cell cultures. Brain Res 462: 372–377PubMedGoogle Scholar
  20. Cherubini E, North RA (1985) μ and κ opioids inhibit transmitter release by different mechanisms. Proc Natl Acad Sci USA 82:1860–1863PubMedGoogle Scholar
  21. Childers SR (1988a) Opiate-inhibited adenylate cyclase in rat brain membranes depleted of Gs-stimulated adenylate cyclase. J Neurochem 50: 543–553PubMedGoogle Scholar
  22. Childers SR (1988b) Opioid receptor-coupled second messenger systems. In: Pasternak GW (ed) The opiate receptors. Humana, Clifton, pp 231–270Google Scholar
  23. Childers SR, Jackson JL (1984) pH Selectivity of N-ethylmaleimide reactions with opiate receptor complexes in rat brain membranes. J Neurochem 43:1163–1170PubMedGoogle Scholar
  24. Childers SR, LaRiviere G (1984) Modification of guanine nucleotide regulatory components in brain membranes: II. Relationship of guanosine-5’triphosphate effects on opiate receptor binding and coupling receptors with adenylate cyclase. J Neurosci 4: 2764–2771PubMedGoogle Scholar
  25. Childers SR, Pasternak GW (1982) Naloxazone a novel opiate antagonist: irreversible blockade of rat brain opiate receptors in vitro. Cell Mol Neurobiol 2: 93–103Google Scholar
  26. Childers SR, Snyder SH (1979) Guanine nucleotides differentiate agonist and antagonist interactions with opiate receptors. Life Sci 23: 759–762Google Scholar
  27. Childers SR, Snyder SH (1980) Differential regulation by guanine nucleotide of opiate agonist and antagonist receptor interactions. J Neurochem 34: 583–593PubMedGoogle Scholar
  28. Childers SR, Lambert SM, LaRiviere G (1983) Selective alterations in guanine nucleotide regulation of opiate receptor binding and coupling with adenylate cyclase. Life Sci 33 (Suppl I): 215–218PubMedGoogle Scholar
  29. Childers SR, Nijssen P, Nadeau P, Buckhannan P, Li P-V, Harris J (1986) Opiate- inhibited adenylate cyclase in mammalian brain membranes. Natl Inst Drug Abuse Res Monogr Ser 71: 65–80Google Scholar
  30. Chou WS, Ho AKS, Loh HH (1971) Effect of acute and chronic morphine and norepinephrine on brain adenylate cyclase activity. Proc West Pharmacol Soc 14: 42–46Google Scholar
  31. Clark MJ, Medzihradsky F (1987) Coupling of multiple opioid receptors to GTPase following selective receptor alkylation in brain membranes. Neuropharmacology 26: 1763–1770PubMedGoogle Scholar
  32. Clark MJ, Levenson SD, Medzihradsky F (1986) Evidence for coupling of the κ opioid receptor to brain GTPase. Life Sci 39: 1721–1727PubMedGoogle Scholar
  33. Clark JA, Houghten R, Pasternak GW (1988) Opiate binding in calf thalamic membranes: a selective mut binding assay. Mol Pharmacol 34: 308–317PubMedGoogle Scholar
  34. Codina J, Yatani A, Grenet D, Brown AM, Birnbaumer L (1987) The a subunit of the GTP binding protein GK opens atrial potassium channels. Science 236: 442–445PubMedGoogle Scholar
  35. Collier HO J, Roy AC (1974) Morphine-like drugs inhibit the stimulation by E prostaglandins of cyclic AMP formation by rat brain homogenates. Nature 248: 24–27Google Scholar
  36. Comb M, Birnberg NC, Seasholtz A, Herbert E, Goodman HM (1986) A cyclic AMP- and phorbol ester-inducible DNA element. Nature 323: 353–356PubMedGoogle Scholar
  37. Comb M, Mermod N, Hyman SE, Pearlberg J, Ross ME, Goodman HM (1988) Proteins bound at adjacent DNA elements act synergistically to regulate human proenkephalin cAMP inducible transcription. Embo J 7: 3793–3805PubMedGoogle Scholar
  38. Cooper DMF, Londos C, Gill DL, Rodbell M (1982) Opiate receptor-mediated inhibition of adenylate cyclase in rat striatal plasma membranes. J Neurochem 38: 1164–1167PubMedGoogle Scholar
  39. Costa T, Herz A (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86: 7321–7325PubMedGoogle Scholar
  40. Costa T, Wuster M, Gramsch C, Herz A (1985) Multiple states of opioid receptors may modulate adenylate cyclase in intact neuroblastoma x glioma hybrid cells. Mol Pharmacol 28: 146–154PubMedGoogle Scholar
  41. Costa T, Klinz FJ, Vachon L, Herz A (1988) Opioid receptors are coupled tightly to G proteins but loosely to adenylate cyclase in NG108-15 cell membranes. Mol Pharmacol 34: 744–754PubMedGoogle Scholar
  42. Costa T, Lang J, Gless C, Herz A (1990) Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. Mol Pharmacol 37: 383–394PubMedGoogle Scholar
  43. Cox BM, Weinstock M (1966) The effects of analgesic drugs on the release of acetylcholine from electrically stimulated guinea-pig ileum. Br J Pharmacol 27: 81–92Google Scholar
  44. Dawson G, McLawhon R, Miller RJ (1980) Inhibition of sialoglycosphingolipid (ganglioside) biosynthesis in mouse clonal lines N4TG1 and NG108-15 by beta endorphin, enkephalins, and opiates. J Biol Chem 255: 129–137PubMedGoogle Scholar
  45. De Lean A, Stadel JM, Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding proterties of the adenylate cyclase-coupled beta- adrenergic receptor. J Biol Chem 255: 1108–1111Google Scholar
  46. Duggan AW, North RA (1983) Electrophysiology of opioids. Pharmacol Rev 35: 219–281PubMedGoogle Scholar
  47. Duman RS, Tallman JF, Nestler EJ (1988) Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus. J Pharmacol Exp Ther 246: 1033–1039PubMedGoogle Scholar
  48. Ehrlich YH, Bonnet KA, Davis LG, Brunngraber EG (1978) Decreased phosphorylation of specific proteins in neostriatal membranes from rats after long-term narcotics exposure. Life Sci 23: 137–146PubMedGoogle Scholar
  49. Fantozzi R, Mullikin-Kirkpatrick D, Blume AJ (1981) Irreversible inactivation of the opiate receptors in neuroblastoma X glioma hybrid NG108-15 cells by chlornaltrexamine. Mol Pharmacology 20: 8–15Google Scholar
  50. Fedynyshyn JP, Lee NM (1989) Mu type opioid receptors in rat periaqueductal gray-enriched P2 membrane are coupled to G-protein-mediated inhibition of adenylyl cyclase. Brain Res 476: 102–109PubMedGoogle Scholar
  51. Florio VA, Sternweis PC (1985) Reconstitution of resolved muscarinic cholinergic receptors with purified GTP-binding proteins. J Biol Chem 260: 3477–3483PubMedGoogle Scholar
  52. Francis B, Moisand C, Meunier JC (1985) Na+ and Gpp(NH)p selectively inhibit agonist interactions at μ- and κ-opioid receptor sites in rabbit and guinea-pig cerebellum membranes. Eur J Pharmacol 117: 223–232Google Scholar
  53. Frey A, Kebabian JW (1984) μ-Opiate receptor in 7315c tumor tissue mediates inhibition of immunoreactive prolactin release and adenylate cyclase activity. Endocrinology 115:1797–1804PubMedGoogle Scholar
  54. Gilbert JA, Richelson E (1983) Function of delta opioid receptors in cultured cells. Mol Cell Biochem 55: 83–91PubMedGoogle Scholar
  55. Gilman AG (1984) G proteins and dual control of adenylate cyclase. Cell 36: 577–579PubMedGoogle Scholar
  56. Greenspan DL, Mussachio JM (1984) The effect of tolerance on opiate dependence as measured by the adenylate cyclase rebound response in the NG108-15 model system. Neuropeptides 5: 41–44PubMedGoogle Scholar
  57. Gross RA, Moises HC, Uhler MD, Macdonald RL (1990) Dynorphin A and cAMP- dependent protein kinase independently regulate neuronal calcium currents. Proc Natl Acad Sci USA 87: 7025–7029PubMedGoogle Scholar
  58. Guitart X, Nestler EJ (1989) Identification of morphine- and cyclic AMP-regulated phosphoproteins (MARPPs) in the locus coeruleus and other regions of rat brain: regulation by acute and chronic morphine. J Neurosci 9: 4371–4387PubMedGoogle Scholar
  59. Gullis RJ (1977) Statement. Nature 265: 764Google Scholar
  60. Gwynn CJ, Costa E (1982) Opioids regulate cyclic GMP formation in cloned neuroblastoma cells. Proc Natl Acad Sci USA 79: 690–694PubMedGoogle Scholar
  61. Hamprecht B (1977) Sturctural, electrophysiological, biochemical, and pharmacological properties of neuroblastoma x glioma cell hybrids in cell culture. Int Rev Cytol 49: 99–170PubMedGoogle Scholar
  62. Harada H, Ueda H, Wada Y, Katada T, Ui M, Satoh M (1989) Phosphorylation of mu-opioid receptors — a putative mechanism of selective uncoupling of receptor — Gi interaction, measured with low-Km GTPase and nucleotide-sensitive agonist binding. Neurosci Lett 100: 221–226PubMedGoogle Scholar
  63. Harada H, Ueda H, Katada T, UM, Satoh M (1990) Phosphorylated mu-opioid receptor purified from rat brains lacks functional coupling with Gil, a GTP- binding protein in reconstituted lipid vesicles. Neurosci Lett 113: 47–49PubMedGoogle Scholar
  64. Hatta S, Marcus MM, Rasenick MM (1986) Exchange of guanine nucleotide between GTP-binding proteins that regulate neuronal adenylate cyclase. Proc Natl Acad Sci USA 83: 5439–5443PubMedGoogle Scholar
  65. Havemann U, Kuschinsky K (1978) Interactions of opiates and prostaglandin E with regard to cyclic AMP in striatal tissue of rats in vitro. Arch Pharmacol 302: 103–106Google Scholar
  66. Heijna MH, Hogenboom F, Portoghese PS, Mulder AH, Schoffelmeer AN (1989) Mu- and delta-opioid receptor-mediated inhibition of adenylate cyclase activity stimulated by released endogenous dopamine in rat neostriatal slices; demonstration of potent delta-agonist activity of bremazocine. J Pharmacol Exp Ther 249: 864–868PubMedGoogle Scholar
  67. Hescheler J, Rosenthal W, Trautwein W, Schultz G (1987) The GTP-binding protein, GO, regulates neuronal calcium channels. Nature 325: 445–447PubMedGoogle Scholar
  68. Hsia JA, Moss J, Hewlett EL, Vaughan M (1984) ADP-ribosylation of adenylate cyclase by pertussis toxin: effects on inhibitory agonist binding. J Biol Chem 259: 1086–1090PubMedGoogle Scholar
  69. Itoh H, Kozasa T, Nagata S, Nakamura S, Katada T, Ui M, Iwai S, Ohtsuka E, Kawasaki H, Suzuki K, Kaziro Y (1986) Molecular cloning and sequence determination of cDNAs for the subunits of the guanine nucleotide-binding proteins Gs, Gi, and GO from rat brain. Proc Natl Acad Sci USA 83: 3776–3780PubMedGoogle Scholar
  70. Itzhak Y (1989) Multiple affinity binding states of the sigma receptor: effect of GTP-binding protein-modifying agents. Mol Pharmacol 36: 512–517PubMedGoogle Scholar
  71. Jakobs KH, Bauer S, Watanabe Y (1985) Modulation of adenylate cyclase of human platelets by phorbol ester. Impairment of the hormone-sensitive inhibitory pathway. Eur J Biochem 151: 425–340PubMedGoogle Scholar
  72. Johnson SM (1990) Opioid inhibition of cholinergic transmission in the guinea-pig ileum is independent of intracellular cyclic AMP. Eur J Pharmacol 180: 331–338PubMedGoogle Scholar
  73. Katada T, Ui M (1982) Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc Natl Acad Sci USA 79: 3129–3133PubMedGoogle Scholar
  74. Katada T, Gilman AG, Watanabe Y, Bauer S, Jakobs KH (1985) Protein kinase C phosphorylates the inhibitory guanine-nucleotide-binding regulatory component and apparently suppresses its function in hormonal inhibition of adenylate cyclase. Eur J Biochem 151: 431–437PubMedGoogle Scholar
  75. Katada T, Oinuma M, Ui M (1986) Mechanisms for inhibition of the catalytic activity of adenylate cyclase by the guanine nucleotide-binding proteins serving as the substrate of islet-activating protein, pertussis toxin. J Biol Chem 261: 5215–5221PubMedGoogle Scholar
  76. Kent RS, De Lean A, Lefkowitz RJ (1980) A quantitative analysis of beta- adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol Pharmacol 17: 14–23PubMedGoogle Scholar
  77. Kobilka BK, Kobilka TS, Daniel K, Regan JW, Caron MG, Lefkowitz RJ (1988) Chimeric α2-β2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. Science 240: 1310–1316PubMedGoogle Scholar
  78. Konkoy CS, Childers SR (1989) Dynorphin-selective inhibition of adenylyl cyclase in guinea pig cerebellum membranes. Mol Pharmacol 36: 627–633PubMedGoogle Scholar
  79. Koski G, Klee WA (1981) Opiates inhibit adenylate cyclase by stimulating GTP hydrolysis. Proc Natl Acad Sci USA 78: 4185–4189PubMedGoogle Scholar
  80. Lambert SM, Childers SR (1984) Modification of guanine nucleotide regulatory components in brain membranes: I. Changes in guanosine-5’-triphosphate regulation of opiate receptor binding sites. J Neurosci 4: 2755–2763PubMedGoogle Scholar
  81. Law PY, Wu J, Koehler JE, Loh HH (1981) Demonstration and characterization of opiate inhibition of the striatal adenylate cyclase. J Neurochem 36: 1834 - 1846PubMedGoogle Scholar
  82. Law PY, Horn DS, Loh HH (1982) Loss of opiate receptor activity in neuroblastoma x glioma NG108-15 hybrid cells after chronic opiate treatment: a multi-step process. Mol Pharmacol 22: 1–4PubMedGoogle Scholar
  83. Law PY, Horn DS, Loh HH (1983a) Opiate receptor down-regulation and desensitization in neuroblastoma x glioma NG108-15 hybrid cells are two separate cellular adaptation processes. Mol Pharm 24: 413–424Google Scholar
  84. Law PY, Griffin MT, Koehler JE, Loh HH (1983b) Attenuation of enkephalin activity in neuroblastoma x glioma NG108-15 hybrid cells by phospholipases. J Neurochem 40: 267–275PubMedGoogle Scholar
  85. Law PY, Ungar HG, Horn DS, Loh HH (1985a) Effects of cycloheximide and tunicamycin on opiate receptor activities in neuroblastoma x glioma NG108-15 hybrid cells. Biochem Pharmacol 34: 9–17PubMedGoogle Scholar
  86. Law PY, Horn DS, Loh HH (1985b) Multiple affinity states of opiate receptors in neuroblastoma x glioma NG108-15 hybrid cells: opiate agonist association rate is a function of receptor occupancy. J Biol Chem 260: 3561–3569PubMedGoogle Scholar
  87. Lefkowitz RJ, Hausdorff WP, Caron MG (1990) Role of phosphorylation in desensitization of the beta-adrenoceptor. Trends Pharmacol Sci 11: 190–194PubMedGoogle Scholar
  88. Le Moine C, Normand E, Guitteny AF, Fouque B, Teoule R, Bloch B (1990) Dopamine receptor gene expression by enkephalin neurons in rat forebrain. Proc Natl Acad Sci USA 87: 230–234PubMedGoogle Scholar
  89. Llinas R, McGuinness TL, Leonard CS, Sugimori M, Greengard P (1985) Intraterminal injection of synapsin I or calcium/calmodulin-dependent protein kinase II alters neurotransmitter release at the squid giant synapse. Proc Natl Acad Sci USA 82: 3035–3039PubMedGoogle Scholar
  90. Louie AK, Law PY, Loh HH (1986) Cell-free desensitization of opioid inhibition of adenylate cyclase in neuroblastoma x glioma NG108-15 hybrid cell membranes. J Neurochem 47: 733–737PubMedGoogle Scholar
  91. Louie AK, Bass ES, Zhan J. Law PY, Loh HH (1990) Attenuation of opioid receptor activity by phorbol esters in neuroblastoma x glioma NG108-15 hybrid cells. J Pharmacol Exp Ther 253: 401–407PubMedGoogle Scholar
  92. Mack KJ, Lee MF, Wehenmeyer J A (1985) Effects of guanine nucleotides and ions on kappa opioid binding. Brain Res Bull 14: 301–306PubMedGoogle Scholar
  93. Makimura M, Murakoshi Y (1989) Kappa-opioid agonists do not inhibit adenylate cyclase. J Pharmacobiodyn 12: 125–131PubMedGoogle Scholar
  94. Makman MH, Dvorkin B, Crain SM (1988) Modulation of adenylate cyclase activity of mouse spinal cord-ganglion explants by opioids, serotonin and pertussis toxin. Brain Res 445: 303–313PubMedGoogle Scholar
  95. Manning DR, Gilman AG (1983) The regulatory components of adenylate cyclase and transducin: a family of structurally homologous guanine nucleotide binding proteins. J Biol Chem 258: 7059–7063PubMedGoogle Scholar
  96. Marckel DR, Childers SR (1989) Opioid receptor second messenger systems. In: Watson RR (ed) Biochemistry and physiology of substance abuse. CRC Press, Boca Raton, pp 155–180Google Scholar
  97. Mattera R, Graziano MP, Yatani A, Zhou Z, Graf R, Codina J, Birnbaumer L, Gilman AG, Brown AM (1989) Splice variants of the alpha subunit of the G protein Gs activate both adenylyl cyclase and calcium channels. Science 243: 804–807PubMedGoogle Scholar
  98. McKenzie FR, Milligan G (1990) Delta-opioid-receptor-mediated inhibition of adenylate cyclase is transduced specifically by the guanine-nucleotide-binding protein Gi2. Biochem J 267: 391–398PubMedGoogle Scholar
  99. Milligan G, Klee WA (1985) The inhibitory guanine nucleotide-binding protein (Ni) purified from bovine brain is a high affinity GTPase. J Biol Chem 260: 2057–2063PubMedGoogle Scholar
  100. Minneman KP, Iversen LL (1976) Enkephalin and opiate narcotics increase cyclic GMP accumulation in slices of rat neostriatum. Nature 261: 313–314Google Scholar
  101. Misawa H, Ueda H, Satoh M (1990) Kappa-opioid agonist inhibits phospholipase C, possibly via an inhibition of G-protein activity. Neurosci Lett 112: 324–327PubMedGoogle Scholar
  102. Mudge AW, Leeman SE, Fischbach GD (1979) Enkephalin inhibits release of substance P from sensory neurons and decreases action potential duration. Proc Natl Acad Sci USA 76: 526–530PubMedGoogle Scholar
  103. Mulder AH, Wardeh G, Hogenboom F, Frankhuyzen AL (1984) κ- and ∂-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release. Nature 308:278–280PubMedGoogle Scholar
  104. Mulder AH, Schoffelmeer AN, Stoof JC (1990) On the role of adenylate cyclase in presynaptic modulation of neurotransmitter release mediated by monoamine and opioid receptors in the brain. Ann NY Acad Sci 60: 237–249Google Scholar
  105. Muraki T, Usamaki H, Kato R (1984) Effect of morphine on the tissue cyclic AMP and cyclic GMP content in two strains of mice. J Pharm Pharmacol 36: 490–492PubMedGoogle Scholar
  106. Nagamatsu K, Suzuki K, Teshima R, Ikebuchi H, Terao T (1989) Morphine enhances the phosphorylation of a 58kDa protein in mouse brain membranes. Biochem J 257: 165–171PubMedGoogle Scholar
  107. Nakamura T, Ui M (1985) Simultaneous inhibitions of inositol-phospholipid breakdown, arachidonic acid release and histamine secretion in mast cells by islet activating protein, pertussis toxin: a possible involvement of the toxin- specific substrate in the calcium-moblizing receptor-mediated biosignalling system. J Biol Chem 260: 3584–3593PubMedGoogle Scholar
  108. Neer EJ, Clapham DE (1988) Roles of G-protein subunits in transmemebrane signalling. Nature 133: 129–133Google Scholar
  109. Neer EJ, Lok JM, Wolf LG (1984) Purification and properties of the inhibitory guanine nucleotide regulatory unit of brain adenylate cyclase. J Biol Chem 259: 14222–14229PubMedGoogle Scholar
  110. Nestler EJ, Tallman JF (1988) Chronic morphine treatment increases cyclic AMP- dependent protein kinase activity in the rat locus coeruleus. Mol Pharmacol 33: 127–132PubMedGoogle Scholar
  111. Nestler EJ, Walaas SI, Greengard P (1984) Neuronal phosphoproteins: physiological and clinical implications. Science 225: 1357–1364PubMedGoogle Scholar
  112. Nestler EJ, Erdos JJ, Terwilliger R, Duman RS, Tallman JF (1989) Regulation of G proteins by chronic morphine in the rat locus coeruleus. Brain Res 476: 230–239PubMedGoogle Scholar
  113. Nishizuka Y (1984) Turnover of inositol phospholipids and signal transduction. Science 225: 1365–1370PubMedGoogle Scholar
  114. North RA, Williams JT, Surprenant A, Christie MJ (1987) μ and ∂ receptors belong to a family of receptors that are coupled to potassium channels. Proc Natl Acad Sci USA 84:5487–5491PubMedGoogle Scholar
  115. Northup JK, Smigel MD, Sternweis PC, Gilman, AG (1983) The subunits of the stimulatory regulatory component of adenylate cyclase: resolution of the activated 45,000-dalton (alpha) subunit. J Biol Chem 258: 11369–11376PubMedGoogle Scholar
  116. Ott S, Costa T, Herz A (1989) Opioid receptors of neuroblastoma cells are in two domains of the plasma membrane that differ in content of G proteins. J Neurochem 52: 619–626PubMedGoogle Scholar
  117. Passarelli F, Costa T (1989) Mu and delta opioid receptors inhibit serotonin release in rat hippocampus. J Pharmacol Exp Ther 248: 299–305PubMedGoogle Scholar
  118. Paton WDM (1957) The action of morphine and related substances on contraction and on acetylcholine output of coaxially stimulated guinea-pig ileum. Br J Pharmacol 12: 119–127Google Scholar
  119. Periyasamy S, Hoss W (1990) Kappa opioid receptors stimulate phosphoinositide turnover in rat brain. Life Sci 47: 219–225PubMedGoogle Scholar
  120. Pfaffinger PJ, Martin JM, Hunter D, Nathanson NM, Hille B (1985) GTP-binding proteins couple cardiac muscarinic receptors to a potassium channel. Nature 317: 536–538PubMedGoogle Scholar
  121. Pfeiffer A, Sadee W, Herz A (1982) Differential regulation of mu-, delta-, and kappa-opiate receptor subtypes by guanine nucleotides and metal ions. J Neurosci 2: 912–917PubMedGoogle Scholar
  122. Polastron J, Boyer MJ, Quertermont Y, Thouvenot JP, Meunier JC, Jauzac P (1990a) Mu-opioid receptors and not kappa-opioid receptors are coupled to the adenylate cyclase in the cerebellum. J Neurochem 54: 562–570PubMedGoogle Scholar
  123. Polastron J, Boyer MJ, Thouvenot JP, Meunier JC, Jauzac P (1990b) Coupling of mu-opioid receptors with adenylate cyclase in naive and morphine tolerant rabbits. Prog Clin Biol Res 328: 25–28PubMedGoogle Scholar
  124. Propst F, Hamprecht B (1981) Opioids, noradrenaline and GTP analogs inhibit cholera toxin activated adenylate cyclase in neuroblastoma x glioma hybrid cells. J Neurochem 36: 580–588PubMedGoogle Scholar
  125. Puri SK, Cochin J, Volicer L (1975) Effect of morphine sulfate on adenylate cyclase and phosphodiesterase activities in rat corpus striatum. Life Sci 16: 759–768PubMedGoogle Scholar
  126. Puttfarcken PS, Cox BM (1989) Morphine-induced desensitization and down- regulation at mu-receptors in 7315C pituitary tumor cells. Life Sci 45: 1937–1942PubMedGoogle Scholar
  127. Puttfarcken PS, Werling LL, Cox BM (1988) Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at μ opioid receptors. Mol Pharmacol 33: 520–527PubMedGoogle Scholar
  128. Quach TT, Tang F, Kageyama H, Mocchetti I, Guidotti A, Meek JL, Costa E, Schwartz JP (1984) Enkephalin biosynthesis in adrenal medulla. Modulation of proenkephalin mRNA content of cultured chromaffin cells by 8-bromo- adenosine 3’,5’-monophosphate. Mol Pharmacol 26: 255–260PubMedGoogle Scholar
  129. Rasenick MM, Childers SR (1989) Modification of Gs-stimulated adenylate cyclase in brain membranes by low pH treatment: correlation with altered guanine nucleotide exchange. J Neurochem 53: 219–225PubMedGoogle Scholar
  130. Rodbell M (1980) The role of hormone receptors and GTP-regulatory proteins in membrane transduction. Nature 284: 17–21PubMedGoogle Scholar
  131. Rothman RB, Long JB, Bykov V, Jacobson AE, Rice KC, Holaday JW (1988) P-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence. J Pharmacol Exp Ther 247: 405–416PubMedGoogle Scholar
  132. Schoffelmeer ANM, Wierenga EA, Mulder AH (1986) Role of adenylate cyclase in presynaptic a2-adrenoceptor- and μ-opioid receptor-mediated inhibition of [3H]- noradrenaline release from rat brain cortex slices. J Neurochem 46: 1711–1717PubMedGoogle Scholar
  133. Schoffelmeer AN, Rice KC, Heijna MH, Hogenboom F, Mulder AH (1988) Fentanyl isothiocyanate reveals the existence of physically associated mu- and delta-opioid receptors mediating inhibition of adenylate cyclase in rat neostriatum. Eur J Pharmacol 149: 179–182PubMedGoogle Scholar
  134. Schofield PR, McFarland KC, Hayflick JS, Wilcox JN, Cho TM, Roy S, Lee NM, Loh HH, Seeburg PH (1989) Molecular characterization of a new immunoglobulin superfamily protein with potential roles in opioid binding and cell contact. Embo J 8: 489–495PubMedGoogle Scholar
  135. Schramm M, Selinger Z (1984) Message transmission: receptor-controlled adenylate cyclase system. Science 225: 1350–1356PubMedGoogle Scholar
  136. Sharma SK, Niremberg M, Klee W (1975a) Morphine receptors as regulators of adenylate cyclase activity. Proc Natl Acad Sci USA 72: 590–594PubMedGoogle Scholar
  137. Sharma SK, Klee WA, Niremberg M (1975b) Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 72: 3092–3096PubMedGoogle Scholar
  138. Sharma SK, Klee WA, Niremberg M (1977) Opiate dependent modulation of adenylate cyclase activity. Proc Natl Acad Sci USA 74: 3365–3369PubMedGoogle Scholar
  139. Sternweis PC, Robishaw JD (1984) Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. J Biol Chem 259: 13806–13813PubMedGoogle Scholar
  140. Sunyer T, Codina J, Birnbaumer L (1984) GTP hydrolysis by pure Ni, the inhibitory regulatory component of adenylyl cyclases. J Biol Chem 259: 15447–15451PubMedGoogle Scholar
  141. Tao P, Law P, Loh HH (1987) Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment. J Pharm Exp Ther 240: 809–816Google Scholar
  142. Tao PL, Chang LR, Law PY, Loh HH (1988) Decrease in delta-opioid receptor density in rat brain after chronic [D-Ala2,D-Leu5]enkephalin treatment. Brain Res 462: 313–320PubMedGoogle Scholar
  143. Tatsumi H, Costa M, Schimerlik M, North RA (1990) Potassium conductance increased by noradrenaline, opioids, somatostatin, and G-proteins: whole-cell recording from guinea pig submucous neurons. J Neurosci 10: 1675–1682PubMedGoogle Scholar
  144. Tell GP, Pasternak GW, Cuatrecasas P (1975) Brain and caudate nucleus adenylate cyclase: effects of dopamine, GTP, E prostaglandins and morphine. FEBS Lett 51: 242–245PubMedGoogle Scholar
  145. Tempel A, Zukin RS, Gardner EL (1982) Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment. Life Sci 31: 1401–1404PubMedGoogle Scholar
  146. Tempel A, Gardner EL, Zukin RS (1985) Neurochemical and functional correlates of nal-trexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther 232: 439–444PubMedGoogle Scholar
  147. Tempel A, Kessler JA, Zukin RS (1990) Chronic naltrexone treatment increases expression of preproenkephalin and preprotachykinin mRNA in discrete brain regions. J Neurosci 10: 741–747PubMedGoogle Scholar
  148. Traber F, Gullis R, Hamprecht B (1975) Influence of opiates on levels of adenosine 3’,5’-monophosphate in neuroblastoma x glioma hybrid cells. Life Sci 16: 1863–1868PubMedGoogle Scholar
  149. Tsai S, Adamik R, Kanaho Y, Halpern JL, Moss J (1987) Immunological and biochemical differentiation of guanyl nucleotide binding proteins: interaction of Goα with rhodopsin, anti-Goα polyclonal antibodies, and a monoclonal antibody against transducin a subunit and Gia. Biochemistry 26: 4728–4733PubMedGoogle Scholar
  150. Tsang D, Tan AT, Henry JL, Lai S (1978) Effect of opioid peptides on noradrenaline-stimulated cyclic AMP formation in homogenates of rat cerebral cortex and hypothalamus. Brain Res 152: 521–527PubMedGoogle Scholar
  151. Ueda H, Uno S, Harada J, Kobayashi I, Katada T, Ui M, Satoh M (1990a) Evidence for receptor-mediated inhibition of intrinsic activity of GTP-binding protein, Gi1 and Gi2, but not G0 in reconstitution experiments. FEBS Lett 266: 178–182PubMedGoogle Scholar
  152. Ueda H, Misawa H, Katada T, Ui M, Takagi H, Satoh M (1990b) Functional reconstruction of purified Gi and Go with mu-opioid receptors in guinea pig striatal membranes pretreated with micromolar concentrations of N-ethylmaleimide. J Neurochem 54: 841–848PubMedGoogle Scholar
  153. Uhl GR, Ryan JP, Schwartz JP (1988) Morphine alters preproenkephalin gene expression. Mol Brain Res 391–397Google Scholar
  154. Vachon L, Costa T, Herz A (1986) GTPase and adenylate cyclase desensitize at different rates in NG108-15 cells. Mol Pharmacol 31: 159–168Google Scholar
  155. Van Inwegen RG, Strada SJ, Robison GA (1975) Effects of prostaglandins and morphine on brain adenylate cyclase. Life Sci 16: 1875–1876PubMedGoogle Scholar
  156. Van Vliet BJ, Mulder AH, Schoffelmeer AN (1990) Mu-opioid receptors mediate the inhibitory effect of opioids on dopamine-sensitive adenylate cyclase in primary cultures of rat neostriatal neurons. J Neurochem 55: 1274–1280PubMedGoogle Scholar
  157. Werling LL, McMahon PN, Cox BM (1989a) Selective changes in mu opioid receptor properties induced by chronic morphine exposure. Proc Natl Acad Sci USA 86: 6393–6397PubMedGoogle Scholar
  158. Werling LL, McMahon PN, Cox BM (1989b) Effects of pertussis toxin on opioid regulation of catecholamine release from rat and guinea pig brain slices. Naunyn Schmiedebergs Arch Pharmacol 339: 509–513PubMedGoogle Scholar
  159. Wilkening D, Mishra RK, Makman MH (1976) Effects of morphine on dopamine- stimulated adenylate cyclase and on cyclic GMP formation in primate brain amygdaloid nucleus. Life Sci 19: 1129–1138PubMedGoogle Scholar
  160. Williams N, Clouet DH (1982) The effect of acute opioid administration on the phosphorylation of rat striatal synaptic membrane proteins. J Pharmacol Exp Ther 220: 278–286PubMedGoogle Scholar
  161. Wojcik WJ, Cavalla D, Neff NH (1985) Co-localized adenosine Al and gamma- aminobutyric acid B (GABAB) receptors of cerebellum may share a common adenylate cyclase catalytic unit. J Pharmacol Exp Ther 232: 62–66PubMedGoogle Scholar
  162. Wolleman M (1981) Endogenous opioids and cyclic AMP. Prog Neurobiol 16: 145–154Google Scholar
  163. Wolozin BL, Pasternak GW (1981) Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci USA 78: 6181–6185PubMedGoogle Scholar
  164. Yatani A, Codina J, Imoto Y, Reeves JP, Birnbaumer L, Brown AM (1987) A G protein directly regulates mammalian cardiac calcium channels. Science 238: 1288–1292PubMedGoogle Scholar
  165. Yu VC, Saddee W (1986) Phosphatidylinositol turnover in neuroblastoma cells: regulation by bradykinin, acetylcholine, but not μ- and ∂-opioid receptors. Neurosci Lett 71: 219–223PubMedGoogle Scholar
  166. Yu VC, Richards ML, Sadee W (1986) A human neuroblastoma cell line expresses mu and delta opioid receptor sites. J Biol Chem 261: 1065–1070PubMedGoogle Scholar
  167. Yu VC, Eiger S, Duan DS, Lameh J, Sadee W (1990) Regulation of cyclic AMP by the mu-opioid receptor in human neuroblastoma SH-SY5Y cells. J Neurochem 55: 1390–1396PubMedGoogle Scholar
  168. Zajac J-M, Roques BP (1985) Differences in binding properties of mu and delta opioid receptor subtypes from rat brain, kinetic analysis and effects of ions and guanine nucleotides. J Neurochem 44: 1605–1614PubMedGoogle Scholar
  169. Zukin RS, Sugarman JR, Fitz-Syage ML, Gardner EL, Zukin SR, Gintzler AR (1982) Naltrexone-induced opiate receptor supersensitivity. Brain Res 245: 285–292PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • S. R. Childers

There are no affiliations available

Personalised recommendations